Rapid response to: Sulfonylureas as second line drugs in type 2 diabetes and the risk of cardiovascular and hypoglycaemic events: population based cohort study

Ruth Cordiner; Imola Nemeth; Ewan Pearson

Rapid response to: Sulfonylureas as second line drugs in type 2 diabetes and the risk of cardiovascular and hypoglycaemic events: population based cohort study

Ruth Cordiner
, Imola Nemeth
, Ewan Pearson

Population Health and Genomics

Research output: Contribution to journal › Comment/debate › peer-review

Original language	English
Article number	k2693
Journal	British Medical Journal
Volume	362
Publication status	Published - 2018

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

https://www.bmj.com/content/362/bmj.k2693/rr-9Licence: CC BY-NC

Cite this

@article{46f6f8dc3eca48dab1bd580a85189207,

title = "Rapid response to: Sulfonylureas as second line drugs in type 2 diabetes and the risk of cardiovascular and hypoglycaemic events: population based cohort study",

author = "Ruth Cordiner and Imola Nemeth and Ewan Pearson",

year = "2018",

language = "English",

volume = "362",

journal = "British Medical Journal",

issn = "0959-8146",

publisher = "BMJ Publishing Group",

}

TY - JOUR

T1 - Rapid response to

T2 - Sulfonylureas as second line drugs in type 2 diabetes and the risk of cardiovascular and hypoglycaemic events: population based cohort study

AU - Cordiner, Ruth

AU - Nemeth, Imola

AU - Pearson, Ewan

PY - 2018

Y1 - 2018

UR - https://doi.org/10.1136/bmj.k2693

M3 - Comment/debate

SN - 0959-8146

VL - 362

JO - British Medical Journal

JF - British Medical Journal

M1 - k2693

ER -

Rapid response to: Sulfonylureas as second line drugs in type 2 diabetes and the risk of cardiovascular and hypoglycaemic events: population based cohort study

UN SDGs

Access to Document

Other files and links

Cite this